Sino Biopharmaceutical's stock price soared 5.00% during intraday trading on Friday, following significant positive developments from the company.

The surge comes after the company announced that its subsidiary Beijing Tide had a New Drug Application (NDA) for a world-first long-acting ropivacaine hydrochloride sustained-release solution for postoperative analgesia accepted by China's Center for Drug Evaluation. Additionally, another subsidiary granted AstraZeneca exclusive ex-China rights to the inhaled respiratory drug TQC3721, which includes a substantial US$200 million upfront payment and potential future milestones worth up to US$1.9 billion.

Simultaneously, Sino Biopharmaceutical expanded its exclusive strategic partnership with GSK, securing commercialization rights for two blockbuster COPD drugs in mainland China. These consecutive global licensing deals have been viewed by analysts as strong validation of the company's internal R&D innovation capabilities, with Goldman Sachs raising earnings estimates and CMB International maintaining a Buy rating on the stock.